Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.32M | 8.73M | 9.47M | 10.42M | 9.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.88M | 78.03M | 81.70M | 65.74M | 59.95M |
| Operating Income | -80.88M | -78.03M | -81.70M | -65.74M | -59.95M |
| Income Before Tax | -70.73M | -70.02M | -72.71M | -55.99M | -53.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.73M | -70.02M | -72.71M | -55.99M | -53.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.73M | -70.02M | -72.71M | -55.99M | -53.34M |
| EBIT | -80.88M | -78.03M | -81.70M | -65.74M | -59.95M |
| EBITDA | -80.88M | -78.01M | -81.70M | -65.74M | -59.95M |
| EPS Basic | -0.90 | -0.99 | -1.05 | -0.81 | -0.90 |
| Normalized Basic EPS | -0.56 | -0.53 | -0.65 | -0.51 | -0.56 |
| EPS Diluted | -0.90 | -0.99 | -1.05 | -0.81 | -0.90 |
| Normalized Diluted EPS | -0.56 | -0.53 | -0.65 | -0.51 | -0.56 |
| Average Basic Shares Outstanding | 78.66M | 70.57M | 69.44M | 69.16M | 59.31M |
| Average Diluted Shares Outstanding | 78.66M | 70.57M | 69.44M | 69.16M | 59.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |